OncoMatch/Clinical Trials/NCT07138209
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Is NCT07138209 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including QLS32015 and Pomalidomide for relapsed or refractory multiple myeloma.
Treatment: QLS32015 · Pomalidomide · Selinexor · Dexamethasone — The purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Prior therapy
Must have received: proteasome inhibitor
Must have received: immunomodulatory drug
Must have received: anti-cd38 monoclonal antibody
Cannot have received: pomalidomide
Cannot have received: selinexor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07138209 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior pomalidomide, selinexor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages